Bambusa Therapeutics develops next‑generation bispecific IgG1 antibodies that simultaneously target two validated cytokine receptors to achieve comprehensive blockade of type 2 inflammatory pathways. Its lead candidates, BBT001 and BBT002, combine IL‑4Rα inhibition with IL‑31 or IL‑5 neutralization, respectively, and incorporate Fc engineering for extended half‑life and reduced dosing frequency, aiming to treat a range of T2 disorders such as atopic dermatitis, asthma, COPD, and eosinophilic esophagitis.
Funding
$49.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with type 2 inflammatory diseases such as atopic dermatitis, asthma, COPD, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis experience persistent symptoms because existing therapies target single cytokines, leading to incomplete suppression of the IL‑4/IL‑13/IL‑5 pathway and risk of disease “leakage.” This results in ongoing inflammation, severe itch‑scratch cycles, and frequent dosing burdens.
Solution
Bambusa Therapeutics develops next‑generation bispecific IgG1 antibodies that simultaneously engage two validated targets to achieve comprehensive blockade of type 2 cytokine signaling. BBT001 pairs IL‑4Rα inhibition with direct IL‑31 neutralization to rapidly relieve itch and improve skin lesions in dermatologic indications. BBT002 combines IL‑4Rα and IL‑5 inhibition to suppress the full spectrum of IL‑4, IL‑13, and IL‑5 activity, addressing eosinophilic inflammation across airway, skin, and gut diseases. Both molecules incorporate Fc engineering to enhance FcRn binding for extended half‑life and Fc mutations that remove unwanted effector functions, enabling less frequent dosing while maintaining high potency.
Target Audience
The primary customers are pharmaceutical partners and clinical development teams seeking advanced biologics for type 2 inflammatory disorders, as well as physicians treating patients with atopic dermatitis, asthma, COPD, chronic rhinosinusitis with nasal polyps, and related eosinophilic conditions.
Features
- Bispecific 2+2 IgG1 format that concurrently binds IL‑4Rα and IL‑31 (BBT001) or IL‑4Rα and IL‑5 (BBT002)
- Fc region engineered for increased FcRn affinity, providing prolonged systemic exposure and longer dosing intervals
- Fc mutations that eliminate effector functions, reducing safety concerns associated with immune activation
- Dual‑target mechanism prevents cytokine “leakage,” delivering more complete inhibition of the type 2 inflammatory cascade
- Designed for multiple T2 indications (dermatology, respiratory, gastrointestinal) with a single platform technology
- Long‑acting formulation supports reduced injection frequency compared with existing monoclonal antibodies